A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC).
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2012
At a glance
- Drugs Firtecan pegol (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 Oct 2012 Planned End Date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
- 04 Jun 2012 Final results were reported at the Annual Meeting of the American Society of Clinical Oncology, and in an Enzon Pharmaceuticals media release.
- 04 Jun 2012 Status changed from active, no longer recruiting to completed.